Appendix 1. Complete clearance results based on Bayesian network meta-analysis

A systematic review (SR) was conducted for the Scottish Medicines Consortium [63] to identify randomized clinical trial (RCT) data from the published literature reporting on the efficacy and safety of AK interventions. There were no restrictions on formulation, dose, mode of delivery or treatment duration in the SR. Following Tables 1A-1C show the databases and search terms used, and hits obtained. Figure 1A depicts the PRISMA flow diagram. Table 1D reports the included and Table 1E the excluded studies.

Table 1A. EMBASE 1980 to 2011 week 18 (09/05/2011) search

	Searches	**Results**
1	ACTINIC KERATOSIS/	3076
2	KERATOSIS/	4311
3	actinic.tw.	4224
4	2 and 3	272
5	1 or 4	3315
6	((actinic or solar) adj keratos$).tw.	2484
7	(ak or aks).tw.	3524
8	or/5-7	6866
9	(peplin or pep005 or “pep 005” or ingenol mebutate).mp.	71
10	(imiquimod or aldara or r837 or r 837 or s26308 or s 26308 or zyclara or zartra).mp.	3854
11	*CRYOTHERAPY/	2419
12	*CRYOSURGERY/	5080
13	(cryotherapy or cryosurgery).mp.	19381
14	(diclofenac or solaraze).mp.	24146
15	(fluorouracil or 5fu or 5 fu or f5u or carac or efudix or efudex or fluoroplex).mp.	85600
16	*salicylic acid/	5557
17	salicylic acid.mp.	24410
18	(tretinoin or aberela or airol or renova or altralin or retin-A or avita or stieva-A).mp.	1852
19	(afamelanotide or scenesse).mp.	24
20	sotirimod.mp.	4
21	LAS41007.mp.	0
22	oleogel.mp.	18
23	*PHOTOCHEMOTHERAPY/	2965
24	*photodynamic therapy/	6058
25	(photochemotherapy or photodynamic therapy or pdt).mp.	18880
26	or/9-25	171760
27	Clinical trial/	831875
28	Randomized controlled trial/	294861
29	Randomization/	54154
30	Single blind procedure/	14245
31	Double blind procedure/	103063
32	Crossover procedure/	30843
33	Placebo/	180074
34	Randomi?ed controlled trial$.tw.	61947
35	Rct.tw.	6890

36	Random allocation.tw.	1035
37	Randomly allocated.tw.	15527
38	Allocated randomly.tw.	1706
39	(allocated adj2 random).tw.	687
40	Single blind$.tw.	11019
41	Double blind$.tw.	118354
42	((treble or triple) adj blind$).tw.	241
43	Placebo$.tw.	158909
44	Prospective study/	168821
45	or/27-44	1138209
46	Case study/	11851
47	Case report.tw.	200093
48	Abstract report/ or letter/	779679
49	or/46-48	987817
50	45 not 49	1105427
51	8 and 26 and 50	562

Table 1B. Ovid MEDLINE(R) In-Process & Other Non-Indexed Citations and Ovid MEDLINE(R) 1948 to 09/05/2011 search

#	**Searches**	**Results**
1	Keratosis, Actinic/	225
2	Keratosis/	6039
3	actinic.tw.	3425
4	2 and 3	863
5	1 or 4	1086
6	((actinic or solar) adj keratos$).tw.	1952
7	(ak or aks).tw.	3373
8	or/5-7	5029
9	(peplin or pep005 or "pep 005" or ingenol mebutate).mp.	25
10	(imiquimod or aldara or r837 or r 837 or s26308 or s 26308 or zartra or zyclara).mp.	1507
11	(fluorouracil or 5fu or 5 fu or f5u or carac or efudex or effudix or nsc18913 or nsc 18913 or nsc19893 or nsc 19893 or fluoroplex).mp.	38272
12	(tretinoin or aberela or airol or renova or altralin or retin-A or avita or stieva-A).mp.	17739
13	*Cryotherapy/	1606
14	*Cryosurgery/	6738
15	(cryotherapy or cryosurgery).mp.	14974
16	(diclofenac or solaraze).mp.	7410
17	*Salicylic Acid/	1242
18	salicylic acid.mp.	7669
19	(afamelanotide or scenesse).mp.	10
20	sotirimod.mp.	0
21	LAS41007.mp.	0
22	oleogel.mp.	11
23	*Photochemotherapy/	8073
24	*Photodynamic therapy/	8073

25	(photochemotherapy or photodynamic therapy or pdt).mp.	14208
26	or/9-25	100516
27	Randomized controlled trials as Topic/	72681
28	Randomized controlled trial/	305699
29	Random allocation/	71251
30	Double blind method/	109596
31	Single blind method/	14866
32	Clinical trial/	462178
33	exp Clinical Trials as Topic/	240326
34	or/27-33	771733
35	(clinic$ adj trial$1).tw.	161144
36	((singl$ or doubl$ or treb$ or tripl$) adj (blind$3 or mask$3)).tw.	109859
37	Placebos/	29537
38	Placebo$.tw.	132156
39	Randomly allocated.tw.	13050
40	(allocated adj2 random).tw.	673
41	or/35-40	334747
42	34 or 41	881036
43	Case report.tw.	166800
44	Letter/	728238
45	Historical article/	273973
46	Review of reported cases.pt.	0
47	Review, multicase.pt.	0
48	or/43-47	1159124
49	42 not 48	855990
50	8 and 26 and 49	240

Table 1C. Cochrane Library (09/05/11) search

ID	Search	Hits
#1	MeSH descriptor Keratosis, Actinic explode all trees	41
#2	(actinic keratosis or solar keratosis):ti,ab,kw	126
#3	(ak or aks):ti,ab,kw	160
#4	(actinic):ti,ab,kw	261
#5	(keratosis):ti,ab,kw	243
#6	(#4 AND #5)	179
#7	(#1 OR #2 OR #3 OR #6)	263
#8	(peplin or pep005 or "pep 005" or ingenol mebutate):ti,ab,kw	3
#9	(imiquimod or aldara or r837 or r 837 or s26308 or s 26308 or zartra or zyclara):ti,ab,kw	164
#10	(imiquimod or aldara or r837 or r 837 or s26308 or s 26308 or zartra or zyclara):ti,ab,kw	164
#11	(fluorouracil or 5fu or 5 fu or f5u or carac or efudex or effudix or nsc18913 or nsc 18913 or nsc19893 or nsc 19893 or fluoroplex):ti,ab,kw	6083
#12	(tretinoin or aberela or airol or renova or altralin or retin-A or avita or stieva-A):ti,ab,kw	636
#13	MeSH descriptor Cryotherapy explode all trees	952
#14	MeSH descriptor Cryosurgery explode all trees	248
#15	(cryotherapy or cryosurgery):ti,ab,kw	918

#16	(diclofenac or solaraze):ti,ab,kw	2432
#17	(salicylic acid):ti,ab,kw	658
#18	MeSH descriptor Photochemotherapy explode all trees	474
#19	(photochemotherapy or photodynamic therapy or PDT):ti,ab,kw	963
#20	(afamelanotide or scenesse):ti,ab,kw	1
#21	(sotirimod):ti,ab,kw	0
#22	(LAS41007):ti,ab,kw	0
#23	(oleogel):ti,ab,kw	1
#24	(#8 OR #9 OR #10 OR #11 OR #12 OR #13 OR #14 OR #15 OR #16 OR #17 OR #18 OR #19 OR #20 OR #21 OR #22 OR #23)	12258
#25	(#7 AND #24)	138



Figure 1A. PRISMA flow diagram

Table 1D. Included studies

First author	Citation
Full publications (n=82)	
Akarsu S	Clinical and Experimental Dermatology, 2011.
Alexiades- Armenakas MR	Archives of Dermatology, 2003. 139 (10): p. 1313-20.
Alirezai M	Journal of the American Academy of Dermatology, 1994. 30 (3): p. 447-451.
Alomar A	British Journal of Dermatology, 2007. 157 (1): p. 133-141.
Anderson L	Journal of the American Academy of Dermatology, 2009. 60 (6): p. 934-943
Apalla Z	Journal of Dermatology. 162 (1): p. 171-175.
Babilas P	British Journal of Dermatology, 2007. 157 (1): p. 111-117.
Babilas P	Journal der Deutschen Dermatologischen Gesellschaft, 2008. 6(1): p. 25-32
Bercovitch L	British Journal of Dermatology, 1987. 116 (4): p. 549-552.
Berlin JM	Journal of drugs in dermatology : JDD, 2008. 7 (7): p. 669-673
Braathen LR	Journal of the European Academy of Dermatology and Venereology, 2009. 23 (5): p. 550-555.
Chen K	Australasian Journal of Dermatology, 2003. 44 (4): p. 250-255
Dragieva G	British Journal of Dermatology, 2004. 151 (1): p. 196-200.
Ericson MB	British Journal of Dermatology, 2004. 151 (6): p. 1204-1212.
Fariba I	Indian Journal of Dermatology, Venereology and Leprology, 2006. 72 (5): p. 346-349.
Fowler JF	Cutis, 2002. 69(6 Suppl): p. 2-7.
Freeman M	Journal of Dermatological Treatment, 2003. 14 (2): p. 99-106.
Gebauer KP	Australasian Journal of Dermatology, 2003. 44 (1): p. 40-43.
Gebauer K	British Journal of Dermatology, 2009, 161 (4): p. 897-903.
Grimaitre M	Dermatology, 2000. 200 (4): p. 346-348.
Hanke CW	Journal of the American Academy of Dermatology, 2010. 62 (4): p. 573-581.
Hantash BM	Archives of Dermatology, 2006. 142 (8): p. 976-982.
Hauschild A	Experimental Dermatology, 2009. 18 (2): p. 116-121
Hauschild A	The British journal of dermatology, 2009;1066-74.
Huyke C	Journal of the German Society of Dermatology, 2009. 7 (2): p. 128-134
Jeffes EW	Journal of the American Academy of Dermatology, 2001. 45 (1): p. 96-104.
Jorizzo J	Journal of the American Academy of Dermatology, 2007. 57 (2): p. 265-268
Jorizzo J	Cutis; cutaneous medicine for the practitioner, 2002. 70 (6): p. 335-339
Jorizzo J	Archives of Dermatology, 2004. 140 (7): p. 813-816.
Jorizzo J	Journal of drugs in dermatology : JDD, 2006. 5 (2): p. 133-139.
Jorizzo J	Journal of drugs in dermatology : JDD. 9 (9): p. 1101-1108.
Jury CS	British Journal of Dermatology, 2005. 153 (4): p. 808-810
Kaufmann R	British Journal of Dermatology, 2008. 158 (5): p. 994-999.
Korman N	Archives of Dermatology, 2005. 141 (4): p. 467-473
Kose O	Journal of Dermatological Treatment, 2008. 19 (3): p. 159-163.
Krawtchenko N	British Journal of Dermatology, 2007. 157 (SUPPL. 2): p. 34-40.
Kurwa HA	Journal of the American Academy of Dermatology, 1999. 41(3 Pt 1); p. 414-8.
Langan SM	British Journal of Dermatology, 2006. 154 (1): p. 146-149.
Lebwohl M	Journal of the American Academy of Dermatology, 2004. 50 (5): p. 714-721.
Levy S	Clinical Therapeutics, 2001. 23 (6): p. 908-920.
Loven K	Clinical Therapeutics, 2002. 24 (6): p. 990-1000.
Marrero GM	Dermatologic Surgery, 1998. 24(9): p. 973-8.
McEwan LE	Australasian Journal of Dermatology, 1997. 38 (4): p. 187-189.
Misiewicz J	Journal of the American Academy of Dermatology, 1991. 24 (3): p. 448-451.
Moloney FJ	British Journal of Dermatology, 2007. 157 (1): p. 87-91.
Moriarty M	Lancet, 1982. 1(8268): p. 364-5.
Morton C	British Journal of Dermatology, 2006. 155(5): p. 1029-36.
Ooi T	British Journal of Dermatology, 2006. 154 (1): p. 72-78.
Ostertag JU	Lasers in Surgery and Medicine, 2006. 38 (8): p. 731-739.
Pariser D	Journal of the American Academy of Dermatology, 2008. 59 (4): p. 569-576.
Pariser DM	Journal of the American Academy of Dermatology, 2003. 48 (2 SUPPL.): p. 227-232.
Piacquadio DJ	Archives of Dermatology, 2004; 41-6.
Radakovic-Fijan S	Journal of the American Academy of Dermatology, 2005. 53 (5): p. 823-827.
Rivers JL	British Journal of Dermatology, 2002. 146 (1): p. 94-100.
Serra-Guillen C	British Journal of Dermatology. 164 (2): p. 429-433.
Shaffelburg M	Journal of drugs in dermatology, 2009. 8 (1): p. 35-39.
Siller G	Australasian Journal of Dermatology, 2009. 50 (1): p. 16-22.
Smith S	Journal of drugs in dermatology, 2003. 2 (6): p. 629-635.
Smith SR	Journal of drugs in dermatology : JDD, 2006. 5 (2): p. 156-159.
Sotiriou E	Journal of the European Academy of Dermatology and Venereology, 2009. 23 (9): p. 1061-1065.
Stockfleth E	Archives of Dermatology, 2002. 138 (11): p. 1498-1502
Swanson N	Journal of the American Academy of Dermatology, 2010. 62 (4): p. 582-590.
Szeimies RM	Journal of the American Academy of Dermatology, 2002. 47 (2): p. 258-262.
Szeimies RM	Dermatologic surgery 2009; 586-92.
Szeimies RM	British Journal of Dermatology. 163 (2): p. 386-394.

Szeimies RM	British Journal of Dermatology, 2010. 162 (2): p. 410-414.
Szeimies RM	Journal of the American Academy of Dermatology, 2004. 51(4): p. 547-55.
Tanghetti E	Journal of drugs in dermatology : JDD, 2007. 6 (2): p. 144-147.
Tan JKL	Journal of Cutaneous Medicine and Surgery, 2007. 11 (6): p. 195-201.
Tarstedt M	Acta Dermato-Venereologica, 2005. 85(5): p. 424-8.
Torres A	Journal of Translational Medicine, 2007. 5(7).
Ulrich C	British Journal of Dermatology, 2007. 157 (SUPPL. 2): p. 25-31.
Ulrich C	European Journal of Dermatology. 20 (4): p. 482-488.
Van Der Geer S	Journal of Dermatological Treatment, 2009. 20 (5): p. 259-265.
Von Felbert V	British Journal of Dermatology. 163 (3): p. 607-615.
Weiss J	Cutis; cutaneous medicine for the practitioner, 2002. 70 (2 Suppl): p. 22-29.
Wennberg AM	Transplantation, 2008. 86 (3): p. 423-429.
Wiegell SR	British Journal of Dermatology, 2009. 160 (6): p. 1308-1314.
Wiegell SR	British Journal of Dermatology, 2008. 158 (4): p. 740-746.
Wolf JE	International Journal of Dermatology, 2001. 40 (11): p. 709-713.
Zeichner JA	Journal of the American Academy of Dermatology, 2009. 60 (1): p. 59-62.
Abstracts (conference proceedings) (n=11)	
Anderson LL	American Academy of Dematology 2010 Annual Meeting, 2010.
Apalla Z	6th Congress of the European Association of Dermatologic Oncology Athens Greece. 2010. 20: p. e73.
Berman B	American Academy of Dematology 2010 Annual Meeting, 2010.
Dirschka T	JDDG - Journal of the German Society of Dermatology. Conference Publication. 9: p. 196-197.
Epstein E	The British journal of dermatology, 2006; 794-5
Lebwohl ML	American Academy of Dematology 2010 Annual Meeting, 2010.
Lee J	Journal of the American Academy of Dermatology, 2010. (var.pagings). 64 (2 SUPPL. 1): p. AB2.
Schmieder G	American Academy of Dematology 2010 Annual Meeting, 2010. P2915.
Spencer J	American Academy of Dematology 2010 Annual Meeting, 2010. P2913.
Swanson N	American Academy of Dematology 2010 Annual Meeting, 2010.
Ulrich C	Journal of the American Academy of Dermatology 2010; (var.pagings): 62 (3 SUPPL. 1): p. AB107.

Table 1E. Excluded studies

Reference (first author, Journal)	**Reason for exclusion**
Clinical study report of PEP-005.	Non-RCT
Dijkstra AT. Journal of the European Academy of Dermatology and Venereology, 2001. 15 (6): p. 550-554	Non-RCT
Dragieva G. Transplantation, 2004. 77(1): p. 115-21.	Non-RCT
FritschC. Photodermatology Photoimmunology and Photomedicine, 1997. 13 (5-6): p. 181-185.	Non-RCT
Hanke CW. Journal of Drugs in Dermatology. 10(2): p. 165-70.	Follow up of previously published and included data
Jeffes EW. Archives of Dermatology, 1997. p: 727-32.	Non-RCT
Lee PK. Dermatologic surgery, 2005. 31 (6): p. 659-664.	Non-RCT
Medina J. Biochemical Pharmacology, 2003. 66(10): p. 1885-95.	In vitro (human reconstructed epidermis), and in vivo using minipigs
Naylor MF. Archives of Dermatology, 1995. 131 (2): p. 170-175.	Treatment – sun protection factor sunscreen (treatment group) and sunscreen base (placebo group)
Perrett CM. British Journal of Dermatology, 2007. 156 (2): p. 320-328.	Mixed study population (epidermal dysplasia : multiple AKs and/or carcinoma in situ). No subgroup results on patients with AKs
Puizina-Ivic N. Collegium antropologicum, 2008. 32 Suppl 2: p. 67-73.	Non-RCT and non-relevant outcome (fluorescence intensity)
Simmonds WL. Cutaneous Medicine for the Practitioner, 1973. 12(1): p. 615-617.	Non-RCT and non-relevant outcome (investigator judgement of whether the treatment area responded better or not)
Tanghetti EA. Cosmetic Dermatology, 2004. 17 (11 SUPPL. 3): p. 16-20.	Non-RCT
Torres A. The British journal of dermatology, 1132-47.	Non relevant outcome - microarray analysis of gene expression from a previous included study
Weinstock MA. Journal of the American Academy of Dermatology, 2009. 61 (2): p. 207-215.	Non-RCT
Wulf HC. Acta Dermato-Venereologica, 2006. 86 (1): p. 25-28.	Mixed study population (actinic keratosis, basal cell carcinoma, warts). No subgroup results on patients with AKs

Outcomes of interest for the purposes of the economic model included complete clearance (CC) rates of AK lesions, AK recurrence rates, time to occurrence of new AK-lesions, and LSRs. CC was defined as no AK lesions remaining following treatment. The SR data were analyzed further in a Bayesian network meta-analysis (NMA) setting to obtain comparative log odds ratios (LOR) for CC rates. The NMA models were fitted to the data using Bayesian Markov Chain Monte Carlo methods (Gibbs sampling), which was conducted using the WinBUGS software version 1.4.1.

To calculate the absolute probability of events occurring for each treatment, the absolute risk for the reference treatment was needed. The reference treatment was chosen to be the treatment that has the most data available. First a (frequentist) random-effects MA was done to pool data on the log-odds of responding to the reference control treatment. The mean and SD pooled log-odds of responding to the reference treatment were then used as priors in the main NMA to inform the calculation of the absolute efficacy of each treatment.



1 Akarsu 2011; 2 Alomar 2007; 3 Anderson 2009; 4 Anderson 2010; 5 Berman 2010; 6 Fariba 2006; 7 Gebauer 2003; 8 Gebauer 2009; 9 Hanke 2010; 10 Hauschild; Szeimies 2009b; 2010b (AK-03); 11 Hauschild; Szeimies 2009b; 2010b (AK-04); 12 Huyke 2009; 13 Jeffes 2001; 14 Jorizzo; Lee 2010; 2011; 15 Jorizzo 2002; 16 Jorizzo 2004; 2006; 17 Jorizzo 2007; 18 Korman 2005; 19 Krawtchenko 2007; 20 Lebwohl 2004; 21 Lebwohl 2010; 22 Loven; Levy 2002; 2001; 23 McEwan 1997; 24 Moriarty 1982; 25 Ooi 2006; 26 Pariser 2003; 27 Pariser 2008; 28 Piacquadio;Fowler 2002 2004;2002; 29 Rivers 2002a; 30 Rivers 2002b; 31 Shaffelburg 2009; 32 Siller 2009; 33 Smith 2003; 34 Stockfleth 2011; 35 Swanson 2010a; 36 Swanson 2010b; 37 Szeimies 2004; 38 Szeimies 2009; 39 Szeimies 2010a; 40 Tan 2007; 41 Tanghetti 2007; 42 Tarstedt 2005; 43 Ulrich 2007; 44 Ulrich 2010a; 2010; 45 von Felbert 2010; 46 Weiss 2002; 47 Wolf 2001

Figure 1B. Network of evidence for the complete clearance

NMAs estimate the relative CC efficacy of each treatment in the network compared with all other treatments in the analysis (Figure 1B). For the NMA of dichotomous endpoints, a binomial likelihood with a logit link was used to calculate the OR for all treatments compared with other treatments. The base case models were random-effects models that allow the true treatment effect to vary between studies due to heterogeneity. In these NMAs, a uniform uninformative prior was used for the between-studies standard deviation. Model fit was assessed using the deviance information criteria.

CC rates were identified for all potential (labeled) AK treatment options. LORs estimated for the treatments were converted to exponents and then applied to the baseline odds of clearance with vehicle gel (placebo). This was achieved by multiplying the odds of CC by the OR with the associated treatment. The odds were then converted to probabilities of CC for use as data inputs in the model. If the odds in favor of CC were known, the probability was calculated as follows: Probability = odds/((1+odds)). Due to the limited available data, a similar NMA was not performed on recurrence rates or LSRs. However, the identified publications were used to estimate figures for recurrences and LSRs. Efficacy data for the analysis are presented in Table 1F below.

Table 1F. Complete clearance for all locations (random effects were used in the base case analysis, relevant comparators shown)

Treatment	***Odds ratio vs. placebo (95% CrI)***		**Value in the CUA, ln(OR)[¥]**
	Fixed effects	*Random effects*	
Cryosurgery	4.395 (1.421,13.12)*	5.438 (0.884,35.27)	1.693
Diclofenac 3% 2x/daily, 12 wks	5.077 (3.283,8.143)*	5.259 (2.027,13.76)*	1.660*
Imiquimod 3.75% 1x/daily, 6 wks	8.855 (5.273,15.84)*	9.101 (2.436,35.57)*	2.208*
Imiquimod 5% 3x/wk, 4 wks	17.17 (10.36,29.81)*	25.47 (7.837,90.13)*	3.238*
Imiquimod 5% 3x/wk, 8 wks	10.4 (0.499,3713)	10.45 (0.304,3185)	2.347
MAL+PDT	208.1 (51.56,824)*	249 (21.63,3055)*	5.517*
IngMeb 0.015% once daily, 3 days	19.88 (10.63,42.27)*	22.15 (5.397,93.47)*	3.098*
IngMeb 0.05% 1x/daily, 2 days	8.726 (5.205,15.18)*	8.868 (2.815,28.21)*	2.182*

wk = week. [¥] Converted from OR to LN(OR). * Credible difference in comparison to placebo.

Appendix 2. Two-year secondary (i.e. specialist) care costs due to actinic keratosis

Table 2A. Secondary care cost results related to actinic keratosis (AK) by the first-line treatment and for patients with incident AK diagnosis (ICD 10 primary diagnosis L57; 10 year controlling; organ transplantation patients excluded) data during calendar year 2009; two-year follow-up from the AK diagnosis

Resources per patient			
1st year	*PDT*	*Cryotherapy*	*Topicals*
Visits	3.8727	1.8434	1.7459
Days	0.0000	0.0000	0.0268
2nd year	*PDT*	*Cryotherapy*	*Topicals*
Visits	0.6909	0.3255	0.3034
Days	0.0000	0.0000	0.0000
Total 2 years	*PDT*	*Cryotherapy*	*Topicals*
Visits	4.5636	2.1689	2.0493
Days	0.0000	0.0000	0.0268
Costs (€2013) per patient			
1st year	*PDT*	*Cryotherapy*	*Topicals*
Treatment	689.06	806.11	300.40
Travelling*	145.34	69.06	69.06
Subtotal	834.40	875.17	369.46
2nd year, not discounted	*PDT*	*Cryotherapy*	*Topicals*
Treatment	122.44	129.68	42.98
Travelling*	25.93	12.19	11.96
Subtotal	148.37	141.87	54.94
2nd year, discounted	*PDT*	*Cryotherapy*	*Topicals*
Treatment	118.77	125.79	41.69
Travelling*	25.15	11.83	11.60
Subtotal	143.92	137.62	53.29
Total 2 years not discounted	*PDT*	*Cryotherapy*	*Topicals*
Treatment	811.50	935.79	343.38
Travelling*	171.27	81.25	81.02
Total	982.77	1017.04	424.40
Total 2 years, discounted	*PDT*	*Cryotherapy*	*Topicals*
Treatment	807.82	931.90	342.09
Travelling*	170.50	80.89	80.66
Total	978.32	1012.79	422.75

Cryotherapy = QAA50, QBA50, QCA50, QDA50, QXA50, ZXC50. PDT = WXQ40–WXQ44, DQ004. *For the societal sensitivity analysis scenario, travelling costs of €37.53/roundtrip travel [100, 101] were also included.